Aviral Singh
Overview
Explore the profile of Aviral Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan T, Patil A, Singh A, Bhavsar G, Ashrith K, Mohanty S
Sci Rep
. 2025 Jan;
15(1):2719.
PMID: 39837968
Indian mythology is a treasure trove of divine tales, yet a gap in understanding still exists between foreign tourists and the rich cultural heritage of Indian deities. To address the...
2.
Sathekge M, Lawal I, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al.
Lancet Oncol
. 2024 Jan;
25(2):175-183.
PMID: 38218192
Background: Actinium-225 (Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of...
3.
Baum R, Schuchardt C, Singh A, Chantadisai M, Robiller F, Zhang J, et al.
J Nucl Med
. 2021 Jun;
63(3):415-423.
PMID: 34168013
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides...
4.
Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, et al.
Nucl Med Mol Imaging
. 2021 Jun;
55(3):136-140.
PMID: 34093893
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe...
5.
Baum R, Singh A, Kulkarni H, Bernhardt P, Ryden T, Schuchardt C, et al.
J Nucl Med
. 2021 Feb;
62(10):1391-1397.
PMID: 33547209
Tb has decay properties similar to those of Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply Tb in...
6.
Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni H, Baum R
J Nucl Med
. 2020 Mar;
61(11):1560-1569.
PMID: 32169914
The objective of this retrospective study was to determine the role of F-FDG PET/CT in a large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated with...
7.
Zhang J, Kulkarni H, Singh A, Baum R
Clin Nucl Med
. 2020 Jan;
45(3):e165-e168.
PMID: 31977464
Radiolabeled somatostatin receptor (SSTR) antagonists have shown promise for imaging neuroendocrine neoplasms and the superiority to SSTR agonists, with lower liver background especially for the sensitive detection of liver metastases,...
8.
Zhang J, Kulkarni H, Singh A, Baum R
Clin Nucl Med
. 2019 Dec;
45(4):e198-e200.
PMID: 31876836
We report here the 12-year survival after the first peptide receptor radionuclide therapy (PRRT) of a patient with metastatic rectal neuroendocrine neoplasms, who received 7 cycles of PRRT with Lu/Y-DOTATATE/DOTATOC...
9.
Bodei L, Kidd M, Singh A, van der Zwan W, Severi S, Drozdov I, et al.
Eur J Nucl Med Mol Imaging
. 2019 Dec;
47(4):895-906.
PMID: 31838581
Purpose: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient...
10.
Zhu W, Zhang J, Singh A, Kulkarni H, Baum R
Clin Nucl Med
. 2019 Oct;
44(12):989-990.
PMID: 31663867
Nasopharyngeal carcinoma may express somatostatin receptors (SSTR). We present a case with metastatic nasopharyngeal carcinoma in the liver, bone, and lymph nodes. The patient was in progression after chemotherapy, external...